Our Mission
The Kennedy's Disease Association's mission is to inform, support, educate, fund research and find a cure for Kennedy's Disease. Get Involved
News & Events
Register for the 2023 KDA Global Conference!
University College London and KD-UK are organizing the first ever London International Kennedy Disease Conference. The conference will be held on November 4 and will incorporate the 2023 KDA annual conference. The first two days of the conference will focus on people living with Kennedy Disease, carriers, carers. The afternoon of Day 2 will focus on current research. For more information and to register for the conference, click here.
Kennedy's Disease Management & Patient Reports
The Kennedy's Disease Association has just added two reports that focus on living life with Kennedy's Disease. The "Voice of the Patient" report summarizes a series of in-person and recorded interviews with individuals living with KD, their caregivers and family members. The "French Protocol for KD Diagnostics & Management Report" provides diagnostic and management recommendations and guidelines for patients with KD and general practitioners. To access these reports, click here.
-
Registration is free. This meeting will conclude the London International Kennedy's Disease Conference that will be held from 4-7 November. This Scientific Conference will cover advances in research and discuss open questions in Kennedy’s disease. These will include the relevance of muscle and CNS in Kennedy’s disease, novel pathogenesis findings, biomarkers and novel therapeutic strategies for this neuromuscular disease.
-
Avenue Therapeutics and AnnJi are excited to announce the first patient to be dosed in the clinical trial of AJ201. There are currently six AnnJi drug trial distribution sites. For more information about the drug and the distribution sites, click here..
-
Nido Biosciences has development NIDO-361, a clinical stage therapeutic targeting the gene mutation that causes Kennedy’s disease. NIDO-361 is a novel small molecule that binds to a distinct site on the androgen receptor and corrects transcriptional dysregulation to restore healthy cell function. The company initiated clinical studies of NIDO-361 in people late last year. For more information on NIDO-361, visit their website by clicking here.
More News
A combination approach of increasing the SIRT3 protein and inhibiting PARPs (poly-ADP ribose polymerase) helps rescue motor endurance of mice modeling the neuromuscular disease spinal bulbar and muscular atrophy also known as Kennedy's disease, according to a new study by Philadelphia College of Osteopathic Medicine (PCOM) researchers.
Researchers at Nagoya University in Japan developed and conducted this survey and are inviting KDA members to participate to allow for a cross-cultural comparison of KD. Upon completion, this research will be published to further the understanding of SBMA transmission among families, improve public knowledge and understanding of SBMA, and to build a foundation for communications between patients and researchers.
